Toxic Shock Syndrome (TSS): Comprehensive Research Report

1. Disease Information

Overview

Toxic Shock Syndrome (TSS) is an acute, rapidly progressive, toxin-mediated multisystem illness caused by exotoxin-producing strains of Staphylococcus aureus (staphylococcal TSS) or Streptococcus pyogenes (Group A Streptococcus; streptococcal TSS, STSS), and rarely group C or G streptococci. The defining pathophysiologic feature is bacterial superantigen exotoxin production that triggers massive, non-specific polyclonal T-cell activation and a resulting cytokine storm, producing high fever, diffuse erythematous ("sunburn-like") rash with later desquamation, hypotension/shock, and multi-organ dysfunction (NCBI Bookshelf StatPearls, NBK459345; PMC10812596, "Toxic Shock Syndrome: A Literature Review," PMID:38247655).

"Central to pathogenesis is TSST-1, which bypasses conventional antigen processing by cross-linking MHC class II molecules on antigen-presenting cells with T cell receptors, triggering massive polyclonal T cell activation and a resultant cytokine storm. The ensuing release of interleukins, tumour necrosis factor and other mediators leads to fever, hypotension and multi-organ dysfunction." (PMC10812596)

TSS is historically associated with high-absorbency tampon use in menstruating women (menstrual TSS, mTSS), but non-menstrual TSS (nmTSS) — arising from surgical-site infections, burns, nasal packing, postpartum/puerperal infection, skin/soft-tissue infection, influenza-associated superinfection, and retained foreign bodies (barrier contraceptives, dialysis catheters) — is now more common than menstrual disease in the U.S. (StatPearls NBK459345; CDC MMWR historical surveillance).

Key Identifiers

ICD-10-CM: A48.3 (Toxic shock syndrome)
ICD-11: 1C45 (bacterial TSS); 1C45.0 (streptococcal TSS)
Orphanet: ORPHA:36234 (Bacterial toxic shock syndrome); ORPHA:99918 (Streptococcal toxic-shock syndrome)
MeSH: D017676 (Shock, Septic — parent category); specific MeSH descriptor "Shock, Toxic" (D014017)
MONDO / OMIM: TSS is an acquired infectious-toxin syndrome, not a monogenic Mendelian disease, so it lacks a dedicated OMIM phenotype MIM number in the classical sense; MONDO cross-references the Orphanet/ICD entities above. (No specific MONDO ID was confirmed in available search results — flagged as a gap for curator lookup via the MONDO OLS browser.)

Synonyms / Alternative Names

Staphylococcal toxic shock syndrome; Streptococcal toxic shock syndrome (STSS); Streptococcal toxic shock-like syndrome (TSLS); Tampon disease (historical, non-preferred); Toxic shock-like syndrome.

Evidence Basis

Information is derived predominantly from aggregated disease-level resources: CDC national notifiable-disease surveillance (active, passive, and enhanced surveillance systems since 1980), case-control epidemiologic studies, case series/cohorts from pediatric and adult ICUs, and structured case reports — rather than large-scale EHR data mining, reflecting TSS's rarity and its status as a nationally notifiable condition in the U.S.

2. Etiology

Disease Causal Factors

TSS is fundamentally an infectious/toxin-mediated disease, not genetic — though host genetic factors modulate susceptibility (see below).

Staphylococcal TSS: caused by toxigenic S. aureus strains producing TSST-1 (toxic shock syndrome toxin-1), and less commonly staphylococcal enterotoxins B and C (SEB, SEC), which act as superantigens. Both MSSA and CA-MRSA strains have been implicated.
Streptococcal TSS (STSS): caused by Streptococcus pyogenes (Group A Streptococcus, GAS) producing streptococcal pyrogenic exotoxins (Spe A, SpeB, SpeC) acting as superantigens, often in the context of invasive soft-tissue infection/necrotizing fasciitis. Rarely, group C or G streptococci cause an analogous syndrome.

"M-proteins, especially types 1 and 3, and the streptococcal pyrogenic exotoxin A (speA) play an important role in the pathogenesis of the infection... M protein is an important virulent determinant of GAS; strains lacking M protein are less virulent." (search synthesis, CDC EID 1995 review; PubMed 9331631)

The most common GAS emm genotypes associated with STSS/shock and multiorgan damage are emm1, emm3, emm12, emm28, and emm89, with the hypervirulent M1_UK lineage recently replacing M1_global in some regions (PMC10825083; PMC11705883, Argentina 2023 genomic surveillance). Mutations in the CovRS two-component regulatory system are implicated in the switch to an invasive/toxigenic phenotype.

Risk Factors

Genetic risk factors: - HLA class II alleles strongly determine the magnitude of the anti-TSST-1 antibody response: HLA-DRB1*03:01 and HLA-DQB1*02:01 are positively associated, while HLA-DRB1*01:01 and HLA-DQB1*05:01 are negatively associated with anti-TSST-1 antibody titers (PMC10507260). Women who fail to seroconvert after TSST-1 exposure may carry HLA class II genotypes associated with a genetically higher intrinsic risk of TSS. - Absence or low titer of neutralizing anti-TSST-1 antibody is considered a core host-susceptibility factor — classic work by Bonventre/Parsonnet-era investigators found antibody levels in TSS cases were significantly lower than in matched controls without a TSS history (search synthesis; PMID:6491377; PMID:17340193).

Environmental / behavioral risk factors: - Use of high-absorbency tampons (historically superabsorbent polyacrylate-containing tampons, withdrawn from market in 1980); tampon oxygen content appears more strongly associated with TSS risk than absorbency or chemical composition per se (ScienceDirect 089543569090105X). - Nasal packing after nasal/sinus surgery — "Nasal packing was used in all patients with TSS and in 98% of all patients" in one post-nasal-surgery case series (PMID:3942641). - Surgical wound infection, postpartum/puerperal infection, burns, retained foreign bodies (diaphragms, cervical caps, dialysis catheters), skin/soft-tissue infection or varicella superinfection, recent influenza infection, and immunocompromised states. - 15–33% of TSS cases occur without an identifiable predisposing risk factor (StatPearls NBK459345).

Protective Factors

Circulating neutralizing antibody to TSST-1 (or to the relevant streptococcal exotoxins) is the principal known protective factor; most adults acquire protective anti-TSST-1 antibody through subclinical colonization/exposure over time.
Removal of superabsorbent tampon formulations from the U.S. market (early 1980s) was followed by a marked decline in menstrual TSS incidence (from 6–12/100,000 in 1980 to ~1/100,000 by 1986) (CDC MMWR historical surveillance).
Beta-lactamase-resistant antistaphylococcal antibiotic therapy after a first episode reduces recurrence risk.

Gene-Environment Interactions

The clearest documented gene-environment interaction is between HLA class II genotype and toxin exposure: "Both toxin exposure and HLA alleles affect the human antibody response to TSST-1" (PMC10507260) — i.e., an individual's genetically determined capacity to mount a neutralizing humoral response, combined with the degree/duration of environmental toxin exposure (e.g., prolonged high-absorbency tampon use enabling S. aureus toxin elaboration in a low-oxygen vaginal microenvironment), jointly determines whether clinical TSS develops after colonization.

3. Phenotypes

TSS phenotypes span symptoms, physical signs, and laboratory abnormalities, with an abrupt onset and rapid (24–48 hour) progression.

Symptoms / Early Prodrome

Sudden-onset high fever, chills, headache, sore throat, vomiting, watery diarrhea, and severe myalgia, typically preceding hypotension and rash by 24–48 hours (search synthesis; HPO suggestion: HP:0001945 Fever; HP:0002018 Nausea and vomiting; HP:0002014 Diarrhea; HP:0003326 Myalgia).

Clinical Signs / Physical Manifestations

Diffuse macular erythroderma ("sunburn-like rash") — HP:0000988 Skin rash / a more specific erythroderma term.
Desquamation, classically palms/soles, occurring 1–2 weeks after rash onset, with full-thickness peeling — HP:0025044 (Desquamation) if available in HPO, or closest matching term.
Strawberry tongue and mucosal hyperemia (oropharyngeal, conjunctival, vaginal) — HP:0031013 (Strawberry tongue).
Hypotension / shock — HP:0002615 (Hypotension) / HP:0001744-adjacent shock terminology.
Peripheral edema, non-pitting edema of hands/feet.
Altered mental status/disorientation without focal neurologic deficits — HP:0007018 (Attention deficit) is not ideal; better: HP:0000733 (Agitation) or generically HP:0002360 (Sleep disturbance) — most fitting is a general "confusion"/"altered consciousness" term (HP:0031466 Confusion or HP:0002015-related encephalopathy term).
Soft-tissue necrosis / necrotizing fasciitis in STSS — HP:0032658 (Skin ulcer)-adjacent or necrosis-specific term.
Conjunctival injection/hyperemia — HP:0000585 (Conjunctivitis) or HP:0000998-adjacent.

Laboratory Abnormalities

Elevated creatine phosphokinase (≥2× ULN) — reflecting myositis/muscle injury.
Elevated BUN/creatinine (≥2× ULN) or sterile pyuria (≥5 WBC/hpf).
Elevated bilirubin/transaminases (≥2× ULN) — hepatic involvement.
Thrombocytopenia (platelets ≤100,000/mm³), often DIC-pattern coagulopathy with prolonged clotting times, low fibrinogen, elevated fibrin degradation products.
Leukocytosis or leukopenia with bandemia/left shift.
Hypocalcemia — described as "prominent throughout the disease" in StatPearls (NBK459345).
Negative blood/CSF cultures for other pathogens (part of the case-definition exclusionary lab criteria); blood cultures may be positive for S. aureus in staphylococcal TSS (unlike STSS, where blood cultures are frequently positive for GAS).

Phenotype Characteristics

Age of onset: any age; menstrual TSS peaks in females aged 15–19 (incidence 1.52/100,000); pediatric STSS is well described; elderly patients with STSS have notably worse prognosis.
Severity: variable, ranging from moderate illness to fulminant multi-organ failure and death within 24–96 hours, especially in STSS.
Progression: acute and rapid — "signs of soft tissue infection... can lead to necrotizing fasciitis... kills 30–60% of patients in 72–96 hours" (search synthesis on STSS/necrotizing fasciitis).
Frequency of organ involvement: by CDC case definition, ≥3 organ systems must be involved for a probable/confirmed staphylococcal TSS diagnosis (GI, muscular, mucous membrane, renal, hepatic, hematologic, CNS).

Quality of Life Impact

Long-term survivor data (see Outcome/Prognosis, §11) document persistent sequelae — cognitive/memory complaints, new-onset allergies, Raynaud phenomenon, dermatitis, and organ-specific hospitalization risk — that can meaningfully affect post-illness quality of life, though most patients recover without major long-term handicap if treated early (toxicshock.com "After TSS"; PMC via ScienceDirect Long-term outcomes cohort study, J Infect 2024).

4. Genetic/Molecular Information

TSS is not caused by a germline pathogenic variant in a human disease gene — there is no "causal gene" in the Mendelian sense. The molecular basis instead resides in bacterial virulence genes:

Staphylococcal TSST-1: encoded by the tst gene, carried on a mobile pathogenicity island (SaPI) in a subset of S. aureus strains; also relevant are sea/sec enterotoxin genes (staphylococcal enterotoxin B/C) as alternative superantigens.
Streptococcal exotoxins: speA, speB, speC genes in S. pyogenes, with M-protein (emm gene) serotype and covRS regulatory mutations modulating invasiveness/toxin expression.

Host Genetic Modifiers

HLA-DRB1/DQB1 class II haplotypes (see §2) modulate the strength and quality of the anti-TSST-1 antibody response and thus host susceptibility — this is the best-characterized human genetic modifier locus for TSS. (HGNC: HLA-DRB1, HLA-DQB1)
No pathogenic germline variant classification (ACMG/AMP), allele frequency in gnomAD, or somatic/germline distinction applies in the conventional sense, since TSS pathophysiology is toxin-driven rather than variant-driven.

Epigenetic / Chromosomal Information

No disease-specific epigenetic signature or chromosomal abnormality has been established for TSS; this section is not applicable in the classical Mendelian-disease sense. (Bacterial mobile genetic elements — SaPIs carrying tst — are the closest analogous "genomic structural feature," but these are bacterial, not human, genomic elements.)

5. Environmental Information

Environmental Factors

Superabsorbent tampon materials (historically carboxymethylcellulose/polyacrylate rayon blends) that increase vaginal oxygen tension and S. aureus toxin elaboration.
Nasal packing materials/tampons used post-surgically.
Retained barrier contraceptive devices (diaphragms, cervical caps, contraceptive sponges).
Surgical wound environments, burns, and postpartum uterine environment as niches for toxigenic organism proliferation.

Lifestyle Factors

Duration of tampon use per cycle and continuous (rather than intermittent) tampon wear.
Not using tampons does not eliminate risk — cases have been documented in women colonized by TSST-1-producing S. aureus who never used tampons, including recurrent TSS despite abstaining from tampon use post-first episode (Lancet Infect Dis systematic review, PMID:31151811).

Infectious Agents

Staphylococcus aureus (toxigenic, TSST-1/SEB/SEC-producing strains, MSSA and MRSA) — NCBI Taxonomy: NCBITaxon:1280.
Streptococcus pyogenes (Group A Streptococcus) — NCBITaxon:1314; rarely group C/G streptococci.
Antecedent viral infection (e.g., influenza, varicella) creating a portal for secondary toxigenic bacterial superinfection is a recognized non-menstrual TSS risk context.

6. Mechanism / Pathophysiology

Causal Chain (Upstream → Downstream)

Colonization/infection with a toxigenic strain (vaginal S. aureus colonization in mTSS; wound/soft-tissue GAS infection in STSS) in a host lacking protective neutralizing antibody.
Superantigen exotoxin production (TSST-1, SEB/SEC for staph; SpeA/B/C for strep) in a permissive microenvironment (e.g., elevated vaginal O₂ tension from tampon use; devitalized/necrotic tissue in soft-tissue infection).
Non-conventional MHC-II/TCR cross-linking: the superantigen binds directly to MHC class II molecules on antigen-presenting cells outside the conventional peptide-binding groove, and simultaneously to the variable β (Vβ) chain of the T-cell receptor, bypassing normal antigen-specific presentation.

"TSST-1... binds to the MHC class II outside the antigen presentation site and the variable beta (Vβ) chain of the T-cell receptor... leading to nonspecific, polyclonal lymphocyte activation of 5-30% of the total population of T cells." (search synthesis on superantigen mechanism; PMC6468478, "Staphylococcal Superantigens: Pyrogenic Toxins Induce Toxic Shock")

Massive polyclonal T-cell activation and cytokine storm: activated T cells and macrophages release TNF-α, TNF-β, IL-1β, IL-2, IL-6, and IFN-γ, plus chemokines such as macrophage chemoattractant protein-1 (MCP-1). Downstream signaling includes MAPK cascades, NF-κB activation, and PI3K/Akt/mTOR pathway engagement.
Systemic inflammatory/vascular effects: cytokine-mediated capillary leak, vasodilation, endothelial activation/dysfunction (demonstrated directly on human aortic endothelial cells, PMID:29229737), and disseminated microvascular injury.
Clinical manifestation: fever, diffuse erythroderma, profound hypotension/distributive shock, and multi-organ dysfunction (renal, hepatic, hematologic/coagulopathy, muscular, CNS), with desquamation as a late cutaneous sequela of the acute inflammatory insult.
In STSS, a parallel/overlapping mechanism involves M-protein-mediated antiphagocytic virulence, enabling invasive soft-tissue infection and necrotizing fasciitis, compounding shock with local tissue destruction and a markedly higher case-fatality rate than staphylococcal TSS.

Cellular Processes

T-lymphocyte hyperactivation and clonal (Vβ-restricted) expansion (e.g., TRBV12-3/12-4+ memory T cells specifically activated by SpeC and TSST-1; PMC9854414).
Macrophage/monocyte activation and inflammatory cytokine secretion.
Vaginal/epithelial cell activation — TSST-1 interacts with CD40 on vaginal epithelial cells to stimulate chemokine production that facilitates local T-cell/macrophage activation (search synthesis; PMC6426597).
Suppression of epithelial autophagy by TSST-1 (PMC4234639).
Endothelial dysfunction and vascular leak.
Neutrophil/complement-mediated tissue injury in soft-tissue necrosis (STSS).

Suggested Ontology Terms

GO:0002347 (response to bacterial pathogen-associated pattern) / GO:0035723 (interleukin-6-mediated signaling pathway) / GO:0033209 (tumor necrosis factor-mediated signaling pathway) / GO:0043123 (positive regulation of I-kappaB kinase/NF-kappaB signaling) for the cytokine/NF-κB cascade.
GO:0002827 (positive regulation of T-helper 1 type immune response) / GO:0042104 (positive regulation of activated T cell proliferation) for polyclonal T-cell activation.
CL:0000084 (T cell), CL:0000235 (macrophage), CL:0000738 (leukocyte), CL:0000115 (endothelial cell), CL:0002144 (capillary endothelial cell) for cell types involved.
CHEBI: TSST-1 and streptococcal pyrogenic exotoxins are proteins rather than small molecules and are better represented as UniProt/GO molecular entities than CHEBI terms.

7. Anatomical Structures Affected

Organ Level

Primary: skin/integument (rash, desquamation), cardiovascular system (hypotension/distributive shock), and the primary infectious site (vaginal mucosa in mTSS; skin/soft tissue, surgical wound, or uterus in nmTSS/STSS).
Secondary/multisystem: kidneys (acute kidney injury, often an early sign preceding hypotension), liver (transaminitis, hyperbilirubinemia), hematologic system (thrombocytopenia, DIC), skeletal muscle (myositis, elevated CPK), gastrointestinal tract (vomiting, diarrhea), and central nervous system (encephalopathy/confusion).
Body systems involved: integumentary, cardiovascular, renal, hepatic, hematologic/immune, musculoskeletal, gastrointestinal, and (in severe STSS) the deep soft-tissue/fascial plane.

Suggested UBERON terms: UBERON:0002097 (skin epidermis), UBERON:0000178 (blood), UBERON:0002113 (kidney), UBERON:0002107 (liver), UBERON:0001134 (skeletal muscle tissue), UBERON:0000948 (heart)/UBERON:0001981 (blood vessel) for the vasculature, UBERON:0000996 (vagina) for the mTSS primary site, UBERON:0002097-adjacent fascia term for STSS necrotizing fasciitis.

Tissue and Cell Level

Vaginal squamous epithelium (site of TSST-1 elaboration and CD40-mediated chemokine induction in mTSS).
Vascular endothelium (aortic/capillary endothelial dysfunction).
Deep fascia and subcutaneous soft tissue (necrotizing fasciitis in STSS).
Peripheral blood T lymphocytes and monocytes/macrophages as the principal toxin-responsive cell populations.

Subcellular Level

MHC class II molecules at the plasma membrane of antigen-presenting cells (GO:0042613, MHC class II protein complex) — the direct molecular docking site for superantigen.
Signal transduction machinery: NF-κB pathway components (nuclear translocation), MAPK cascade proteins, PI3K/Akt/mTOR pathway components — largely cytoplasmic/nuclear.

Localization

Bilateral/systemic — TSS is a systemic toxin-mediated disease without lateralization; cutaneous rash is typically diffuse and symmetric.

8. Temporal Development

Onset

Age: can occur at any age (neonatal through geriatric); menstrual TSS is essentially confined to menstruating individuals (peak 15–19 years); pediatric non-menstrual TSS and STSS are well documented (PMID:29601458, "Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children").
Onset pattern: acute — sudden onset of fever/flu-like prodrome, with hypotension, rash, and multi-organ involvement developing within 24–48 hours.

Progression

Disease course: rapid and fulminant, particularly STSS with necrotizing fasciitis, which "kills 30–60% of patients in 72–96 hours" absent aggressive intervention.
Progression rate: STSS-associated mortality has been reported to exceed 25% within the first 24 hours in some cohorts.
Disease duration: acute, self-limited illness with appropriate treatment (source control + antibiotics + supportive care); desquamation phase resolves over 1–2+ weeks after the acute illness.
Recurrence is well documented in menstrual TSS (up to ~14/44 cases in early cohorts having ≥1 recurrence), particularly without antistaphylococcal antibiotic therapy or continued tampon use; recurrence can occur even after tampon cessation in colonized women.

Patterns

Remission: typically treatment-induced (source control + antibiotics + supportive/ICU care) rather than spontaneous, though the disease is not chronic — surviving patients generally achieve full clinical resolution of the acute episode.
Critical periods: early recognition and rapid initiation of source control (tampon/foreign body removal, wound debridement) plus toxin-suppressing antibiotic therapy (clindamycin) within the first hours of presentation are repeatedly emphasized as the key modifiable window affecting mortality.

9. Inheritance and Population

Epidemiology

Overall U.S. incidence: ~0.8–3.4 per 100,000 (StatPearls NBK459345), though estimates vary substantially by era and surveillance method.
Menstrual TSS incidence: historically 6–12/100,000 women aged 12–49 (1980), declining to ~1/100,000 women 15–44 by 1986 following superabsorbent tampon withdrawal; current estimates ~0.5–1.0/100,000; peak incidence 1.52/100,000 in women 15–19.
Non-menstrual TSS: now exceeds menstrual TSS incidence; by 1986, menstrual vs. non-menstrual rates were roughly 1 vs. 0.3/100,000, with the gap subsequently reversing.
Streptococcal TSS (STSS): annual incidence ~1/300,000–1/1,000,000 per Orphanet; alternative estimates of 2–4 cases per 100,000 per year have also been reported; STSS accounts for ~4% of invasive GAS disease overall.
Worldwide bacterial TSS prevalence: estimated at ~1/30,000 (Orphanet).

Inheritance Pattern

TSS is not a Mendelian genetic disease — there is no inheritance pattern (AD/AR/X-linked/mitochondrial) in the classical sense. Susceptibility is polygenic/immunogenetic, chiefly modulated by HLA class II genotype, which affects antibody-mediated protection but does not itself "cause" disease. Penetrance, expressivity, anticipation, germline mosaicism, and carrier-frequency concepts are not applicable.

Population Demographics

Sex ratio: menstrual TSS is essentially female-only by definition; across all TSS (menstrual + non-menstrual), approximately 85% of cases occur in females and 15% in males (search synthesis).
Race/ethnicity: historical U.S. surveillance found higher menstrual TSS incidence in white women than non-white women (1.21/100,000 vs. 0.34/100,000).
Age distribution: bimodal relevance — menstrual TSS peaks in adolescent/young adult females (15–19 years); non-menstrual and streptococcal TSS occur across the age spectrum, with STSS notably more severe/lethal in elderly patients.
Geographic distribution: occurs worldwide; STSS/invasive GAS disease shows regional variation in dominant emm genotypes (e.g., emm1/M1_UK lineage replacement documented in parts of Europe; emm1-global and hypervirulent emm1 lineages highlighted in South American surveillance).
Seasonality: StatPearls notes TSS occurs year-round but with somewhat higher winter prevalence, and increased frequency reported in developing nations.

10. Diagnostics

Clinical Case Definition (CDC, 2011 — Staphylococcal TSS)

All five clinical criteria are required for a confirmed case (or death before desquamation occurs); four of five plus laboratory criteria define a probable case:

Fever: temperature ≥102.0°F (≥38.9°C)
Rash: diffuse macular erythroderma
Desquamation: 1–2 weeks after rash onset (palms/soles classically)
Hypotension: systolic BP ≤90 mmHg (adults) or <5th percentile for age (children <16)
Multisystem involvement (≥3 of the following):
Gastrointestinal (vomiting or diarrhea at onset)
Muscular (severe myalgia or CPK ≥2× ULN)
Mucous membrane (vaginal, oropharyngeal, or conjunctival hyperemia)
Renal (BUN/creatinine ≥2× ULN, or pyuria ≥5 WBC/hpf without UTI)
Hepatic (bilirubin or transaminases ≥2× ULN)
Hematologic (platelets <100,000/mm³)
CNS (disorientation/altered consciousness without focal signs, in the absence of fever/hypotension)

Laboratory criteria: negative blood/CSF cultures (blood culture may be positive for S. aureus) and negative serologies for Rocky Mountain spotted fever, leptospirosis, and measles. (Source: CDC National Notifiable Diseases case-definition portal, ndc.services.cdc.gov)

Streptococcal TSS clinical criteria are analogous but require hypotension plus ≥2 of: renal impairment, coagulopathy, hepatic involvement, ARDS, generalized erythematous macular rash, and soft-tissue necrosis/necrotizing fasciitis, together with isolation of S. pyogenes (from a sterile site for a confirmed case; non-sterile site for probable).

Laboratory Tests

No single specific diagnostic test exists; diagnosis is clinical/syndromic per case-definition criteria.
CBC (leukocytosis or leukopenia with bandemia, thrombocytopenia, anemia), comprehensive metabolic panel (renal/hepatic function), creatine phosphokinase, coagulation studies (PT/PTT, fibrinogen, D-dimer for DIC), blood/wound/vaginal cultures.
Acute kidney injury is frequently the earliest organ-injury sign, often preceding hypotension.
Hypocalcemia is a notable and prominent laboratory abnormality throughout the illness course.

Genetic Testing

Not applicable/not indicated for diagnosis — TSS is not diagnosed via genetic testing (no WGS/WES/gene panel/CMA/karyotype role), reflecting its infectious/toxin-mediated (not germline) etiology. HLA typing has research relevance for susceptibility studies but is not part of routine clinical diagnostics.

Imaging / Other

CT/MRI may be used adjunctively to evaluate for necrotizing fasciitis extent or abscess/retained foreign body in non-menstrual TSS, but imaging is not part of the core case definition.

Differential Diagnosis

Scarlet fever, Kawasaki disease, meningococcemia, toxic epidermal necrolysis/Stevens-Johnson syndrome, necrotizing fasciitis (as a co-occurring/overlapping entity in STSS), drug eruptions, erythema multiforme, and — in pediatric populations — multisystem inflammatory syndrome in children (MIS-C) (PMC10056689, comparative pediatric study of MIS-C, Kawasaki disease, and TSS).

Screening

No population-based screening program exists; risk-reduction counseling (tampon absorbency/duration, foreign-body management) functions as informal primary prevention rather than formal screening.

11. Outcome/Prognosis

Survival and Mortality

Staphylococcal (non-streptococcal) TSS: case-fatality generally <3%, with some modern series citing an overall range of 1.8–12%.
Streptococcal TSS (STSS): substantially higher mortality — commonly cited as 30–60%, with some sources reporting up to 80% in adults versus 5–8% in children; a Japanese nationwide investigation found an overall mortality rate of 45%; STSS-associated mortality can exceed 25% within the first 24 hours.
When STSS is complicated by necrotizing fasciitis, mortality of 30–60% within 72–96 hours has been reported.
STSS accounts for a small fraction (~4%) of invasive GAS disease overall but disproportionately drives GAS-associated mortality (~38% case-fatality cited for STSS specifically in some series).
Delayed diagnosis/treatment is consistently identified as a major driver of increased mortality across both staphylococcal and streptococcal TSS.

Morbidity and Long-Term Function

Reported long-term sequelae in survivors include: late-onset rash, compromised renal function, cyanotic extremities, prolonged neuromuscular abnormalities, dermatitis, new-onset allergies, and Raynaud phenomenon.
Neurocognitive sequelae are notable: EEG abnormalities, difficulty concentrating, headache, and memory lapses are described post-recovery, with one study finding survivors had reduced left hippocampal volume compared to healthy controls.
A recent matched cohort study (J Infect 2024) found TSS "strongly associated with the risk of renal, cardiovascular, and hepatic hospitalization" in the post-acute period.
Severe complications include digit/limb gangrene (potentially requiring amputation) and renal failure, though these are described as rare with early, aggressive treatment.
Overall, "most patients recover completely and without any significant long-term handicap" when treated promptly.

Prognostic Factors

Organism (streptococcal >> staphylococcal severity), timeliness of diagnosis/source control, presence/extent of necrotizing soft-tissue infection, patient age (elderly patients with STSS fare markedly worse), and emm genotype (emm1/emm3/emm89 associated with more severe invasive disease).

12. Treatment

Pharmacotherapy

Empiric broad-spectrum antibiotics pending culture identification, typically including vancomycin or linezolid for MRSA coverage.
Clindamycin is added specifically as an antitoxin/protein-synthesis-inhibiting adjunct — it suppresses toxin (TSST-1/streptococcal exotoxin) and cytokine production independent of its bactericidal action; "studies demonstrate improved outcomes when clindamycin is added" (StatPearls NBK459345). IDSA recommends penicillin + clindamycin combination therapy for confirmed streptococcal TSS.
Once organism/susceptibility is confirmed: penicillin for Group A Streptococcus; clindamycin plus an antistaphylococcal penicillin (nafcillin/oxacillin/flucloxacillin) for MSSA.
Typical antibiotic duration: 7–14 days.
NCIT term: NCIT:C15632 (Chemotherapy) is not appropriate; more fitting is NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bindings to CHEBI (e.g., CHEBI for clindamycin, vancomycin, penicillin, linezolid).

Advanced/Adjunctive Therapeutics

Intravenous immunoglobulin (IVIG): proposed mechanism is direct neutralization of circulating superantigen. Evidence is mixed:
A systematic review/meta-analysis of clindamycin-treated STSS patients found mortality fell from 33.7% to 15.7% with IVIG "with remarkable consistency across the single randomized and four nonrandomized studies" (PMC6186853; Clin Infect Dis, PMID referenced in search).
However, a more recent large observational Japanese nationwide study found no significant survival benefit of IVIG after adjustment for confounders, and the single multicenter RCT (Darenberg et al.) was terminated early due to slow recruitment.
Typical proposed dosing: high-dose IVIG, ~2 g/kg, though it remains without definitive RCT-level mortality benefit and guideline recommendations vary.
Corticosteroids: not recommended — no demonstrated mortality benefit.

Surgical/Interventional

Immediate removal of the inciting foreign body (tampon, nasal packing, retained barrier contraceptive/surgical material) is a first-line, urgent intervention.
Emergent surgical debridement/source control for infected/necrotic soft tissue, particularly critical in STSS with necrotizing fasciitis — described as "critical to outcomes."
NCIT term: NCIT:C15329 (Surgical Procedure) / NCIT:C154430 (debridement-related term).

Supportive Care

Aggressive IV crystalloid fluid resuscitation for hypotension.
Vasopressors (norepinephrine preferred) for fluid-refractory shock.
Electrolyte repletion, notably for hypocalcemia.
ICU admission mandatory for all patients; severe cutaneous/desquamating cases may require burn-unit-level care.
NCIT term: NCIT:C15747 (Supportive Care).

Experimental / Preventive Immunotherapy

rTSST-1v (recombinant detoxified TSST-1 variant) vaccine — Phase 1 (PMID:27296693, Lancet Infect Dis 2016) and Phase 2 trials (NCT02814708; PMC10808908, eClinicalMedicine) demonstrate the vaccine is safe, well-tolerated, and highly immunogenic: "Seroconversion occurred in >81% of subjects within 3 months of the first immunisation, sustained until 18 months after the third immunisation in over 70% of subjects." This represents a first-in-class active immunoprophylaxis approach targeting the core superantigen mechanism.
Passive TSST-1-neutralizing monoclonal/single-chain antibody approaches have shown protective efficacy in animal models even when administered late in toxin exposure (PMC4073126; PMC9617332).

Treatment Algorithm Summary

Recognize (case-definition criteria) → remove foreign body/source control → empiric broad-spectrum antibiotics (vancomycin/linezolid + clindamycin) → narrow per culture/organism → aggressive fluid resuscitation ± vasopressors → consider IVIG in refractory/severe STSS → ICU-level supportive care → surgical debridement if soft-tissue necrosis.

13. Prevention

Primary Prevention

Avoidance of superabsorbent tampon formulations (regulatory withdrawal of the highest-absorbency products was a landmark U.S. public-health primary-prevention action in the early 1980s, associated with a large decline in menstrual TSS incidence).
Guidance on tampon use duration/frequency and alternating with pads to reduce continuous high-absorbency exposure.
Careful surgical technique and judicious nasal-packing use/duration following nasal/sinus surgery.
Immunization: no licensed vaccine yet exists, but the rTSST-1v candidate vaccine (Phase 2 completed) represents an active primary-prevention strategy in development, specifically for individuals at recognized risk (e.g., prior TSS survivors, given documented recurrence risk).

Secondary Prevention / Early Detection

Clinical vigilance and rapid application of case-definition criteria in any patient with fever + rash + hypotension, particularly post-surgical, postpartum, or menstruating patients, to enable early source control and antibiotic initiation — repeatedly identified as the single greatest modifiable determinant of survival.
Recommendation for beta-lactamase-resistant antistaphylococcal antibiotic therapy after a first TSS episode to reduce recurrence.

Tertiary Prevention

Post-TSS antistaphylococcal therapy and discontinuation of causative tampon/device use to prevent recurrent episodes, recognizing that recurrence can still occur even after risk-factor removal in colonized individuals.

Public Health / Chemoprophylaxis

The CDC does not recommend routine screening or chemoprophylaxis for household contacts of streptococcal TSS cases; however, providers "may choose to offer chemoprophylaxis to household members aged ≥65 years or those at increased risk," with a suggested regimen of 7–10 days of oral cephalexin (StatPearls NBK459345).
Standard/contact/droplet precautions are recommended for the first 24 hours of effective antibiotic therapy in hospitalized STSS patients.

Counseling

No formal genetic counseling role exists given the non-Mendelian, infectious nature of TSS; counseling is limited to behavioral/device-use risk-reduction education, particularly for TSS survivors regarding recurrence risk.

14. Other Species / Natural Disease

Taxonomy

TSS-like disease is described in domestic dogs (Canis lupus familiaris, NCBITaxon:9615), driven by superantigen-producing Staphylococcus and Streptococcus species.

Natural Disease in Animals

Canine Streptococcal Toxic Shock Syndrome (CSTSS): primarily caused by Streptococcus canis, described as "a serious often fatal disease syndrome seen in dogs" (Veterinary World review, veterinaryworld.org).
Case reports document mixed infections, e.g., S. aureus, Streptococcus halichoeri, and Dermatophilus spp. co-infection producing a toxic shock-like syndrome in a dog (Vet Sci 2025, doi:10.3390/vetsci12080764; PMC12390649).
Clinical presentation parallels the human disease: superantigen-driven massive TNF-α and inflammatory cytokine release, high fever, hypotension, hemoconcentration, thrombosis, and neutrophil/endothelial activation leading to multi-organ failure.
No OMIA (Online Mendelian Inheritance in Animals) entry was identified for TSS, consistent with its non-heritable, infectious basis — this is expected given TSS is toxin/infection-driven rather than a Mendelian trait, and is flagged as an appropriate "not applicable" rather than a knowledge gap.

Comparative Biology

The rabbit is considered the classic experimental model of choice for human TSS specifically because of its comparable sensitivity to staphylococcal/streptococcal superantigens (see Model Organisms, §15) — this cross-species conservation of superantigen sensitivity underscores that the core MHC-II/TCR superantigen mechanism is broadly conserved across mammals, with canine natural disease representing a spontaneous, naturally occurring parallel to the human syndrome.

Zoonotic Considerations

TSS itself is not classically zoonotic (human and canine cases arise from largely host-adapted or opportunistic staphylococcal/streptococcal strains rather than direct animal-to-human transmission), though S. canis is a recognized opportunistic pathogen that can rarely cause human infection.

15. Model Organisms

Rabbit Model (Primary Model)

The rabbit is explicitly identified as "the experimental model of choice because it is comparable to humans in its sensitivity to superantigens" (search synthesis; PMC3153295, PMID:22069685). - Intravaginal TSST-1 administration in rabbits produces 100% lethality in unprotected controls, closely modeling menstrual TSS. - Multiple-dose lethal-challenge protocols (repeated dosing over 5 days) are used to model sustained toxin exposure; TSST-1-neutralizing antibody treatment is fully protective in this model, including when administered late in the course of exposure (PMC4073126) — directly informing the rationale for passive/active immunotherapy development. - A chronic-exposure rabbit model further demonstrated that sustained low-level TSST-1 exposure accelerates atherosclerosis progression (PMC6933490), illustrating a vascular/endothelial dimension of chronic superantigen exposure beyond acute shock. - TSST-1 mutant analysis in rabbits established that T-cell activation is mechanistically required for the biological effects of the toxin, including the cytokine storm itself (PMC3153295).

Mouse Models

Wild-type mice are relatively resistant to staphylococcal/streptococcal superantigens due to poor toxin-MHC class II binding affinity — a significant translational limitation.
HLA class II-transgenic mice (e.g., HLA-DQ8 transgenic) overcome this: "Transgenic expression of human HLA class II can render mice superantigen sensitive and allows investigation of superantigen-associated inflammation without the need for sensitization." Spleen cells from HLA-DQ8 transgenic mice show markedly greater TSST-1 sensitivity than wild-type C57BL/6 cells.
A transgenic mouse model of staphylococcal soft-tissue infection was used to evaluate TSST-1 production in vivo and assess antibiotic impact — early clindamycin treatment altered TSST-1 production in soft tissue and immune organs, directly modeling the toxin-suppression rationale for clindamycin adjunctive therapy in human TSS (PMC6796978, mSphere, "Toxic Shock Syndrome Toxin 1 Evaluation and Antibiotic Impact in a Transgenic Model of Staphylococcal Soft Tissue Infection").

Model Characteristics: Fidelity and Limitations

Recapitulation: both rabbit and HLA-transgenic mouse models successfully reproduce the core superantigen-driven cytokine storm and lethality; the rabbit model in particular captures the acute lethal shock phenotype with high fidelity.
Limitations: standard (non-transgenic) mouse strains fail to recapitulate human-relevant superantigen sensitivity because murine MHC class II binds staphylococcal/streptococcal superantigens poorly — this is a well-recognized species-specific translational gap, addressed only by HLA-humanized transgenic approaches. Rabbit models, while pharmacodynamically closer to human superantigen sensitivity, do not fully capture the human menstrual/vaginal microbiome context in which TSST-1 is naturally elaborated.

Applications

Rabbit and HLA-transgenic mouse models have been used to: (1) establish the causal, T-cell-activation-dependent mechanism of superantigen-induced cytokine storm and lethality; (2) test neutralizing antibody therapeutics (fully protective even late in exposure); (3) evaluate the rTSST-1v vaccine candidate's immunogenicity prior to human trials; and (4) evaluate antibiotic (clindamycin) impact on in vivo toxin production, directly supporting current clinical antitoxin treatment strategy.

Resources

No dedicated TSS-specific model-organism database exists; relevant models are documented in the primary immunology/infectious-disease literature cited above rather than centralized repositories like MGI/IMPC (reflecting that these are typically custom-generated transgenic/challenge models rather than heritable knockout lines cataloged for a Mendelian phenotype).

Summary of Suggested Ontology Term Bindings for KB Curation

Table (click to expand)

Category	Suggested Term(s)
Disease identifiers	ICD-10-CM A48.3; ICD-11 1C45 / 1C45.0; ORPHA:36234 (bacterial TSS); ORPHA:99918 (streptococcal TSS); MONDO term to be confirmed via OLS lookup
Causal organisms	NCBITaxon:1280 (Staphylococcus aureus); NCBITaxon:1314 (Streptococcus pyogenes)
Causal gene (bacterial virulence)	tst (TSST-1), sea/sec (staph enterotoxins), speA/speB/speC (strep exotoxins) — bacterial, not HGNC-mapped
Host modifier genes	HLA-DRB1, HLA-DQB1 (HGNC)
Key phenotypes (HP)	Fever HP:0001945; Hypotension HP:0002615; Strawberry tongue HP:0031013; Myalgia HP:0003326; Diarrhea HP:0002014; Thrombocytopenia HP:0001873
Molecular mechanism (GO)	MHC class II protein complex GO:0042613; TNF-mediated signaling GO:0033209; positive regulation of T cell proliferation GO:0042129/GO:0042104
Cell types (CL)	CL:0000084 T cell; CL:0000235 macrophage; CL:0000115 endothelial cell
Anatomy (UBERON)	UBERON:0002097 skin; UBERON:0000996 vagina; UBERON:0002113 kidney; UBERON:0002107 liver
Treatments (NCIT)	NCIT:C15986 Pharmacotherapy (clindamycin, vancomycin, penicillin — CHEBI-bound `therapeutic_agent`); NCIT:C15329 Surgical Procedure; NCIT:C15747 Supportive Care
Model organisms	Rabbit (Oryctolagus cuniculus); HLA-DQ8-transgenic mouse

Key knowledge gaps flagged for curation: no confirmed dedicated MONDO ID was retrieved in this search pass (should be verified directly against the MONDO OLS browser); IVIG mortality benefit remains genuinely contested in the primary literature (meta-analytic pooled benefit vs. large adjusted observational null-result) and should be curated as a HUMAN_MODEL_MISMATCH/conflicting-evidence discussion rather than a settled treatment-efficacy claim; no OMIA entry exists for the canine analog, consistent with the non-heritable, infectious nature of the disease.